key: cord-0964772-ylkjxuxq authors: Kurita, J.; Sugawara, T.; Sugishita, Y.; Ohkusa, Y. title: No Excess Mortality of COVID-19 in Japan until April, 2020 date: 2020-07-11 journal: nan DOI: 10.1101/2020.07.09.20143164 sha: 5ff8e11a3a78992360a8babc870ab0b250419846 doc_id: 964772 cord_uid: ylkjxuxq Background: As of the end of June, 2020, the COVID-19 outbreak exhibited its highest peak on April 3. Nevertheless, no remarkable excess mortality attributable to COVID-19 has been observed. Object: We sought to quantify excess mortality in April using the National Institute of Infectious Diseases (NIID) model. Method: We applied the NIID model to deaths of all causes from 1987 up through April, 2020. Results: Results show no significant excess mortality in March or April, 2020, when the COVID-19 outbreak affected Japan most. Discussion and Conclusion: Because changes in application rule of the International Classification of Diseases in 2017 affected the number of pneumonia deaths drastically, we were unable to use pneumonia deaths to estimate excess mortality. it might be important to continue to monitor excess mortality of COVID-19 carefully after May 2020. To date, excess mortality has mainly been used to assess the social effects of influenza activity [1-6]. However, since the emergence of COVID-19, excess mortality attributable to COVID-19 has been attracting attention [7] as a measure of the total effects of the disease because it can reflect cases which have not been identified as polymerase chain reaction (PCR) positive. Especially in Japan, PCR tests administered per capita have been few. Therefore, concern has arisen about the possibility that some deaths caused by COVID-19 have not been recognized heretofore. Moreover, excess mortality related to COVID-19 might be expected to contribute to evaluation of vaccine effects. For these evaluations, the estimated excess mortality without the effects of a vaccine should be regarded as a baseline. Nevertheless, no such a trial has been undertaken to date. This study might be the first trial to measure that figure in Japan. As of the end of June, 2020, the COVID-19 outbreak showed its highest peak on . In this sense, one might regard the number of deaths as reflecting the actual situation in Japan, but with no testing-related bias. Concerning deaths, the case-fatality rate (CFR) is about 5%. In fact, the CFRs in both countries are not much different. The lower PCR testing in Japan might be related to some problems. Therefore, we specifically examined excess mortality attributable to COVID-19 in Japan, irrespective of the cause of death. In Japan, excess mortality was estimated using the National Institute of Infectious Diseases (NIID) model [10] , which has been the official procedure for more than ten years. It was applied to two data sources: the national monthly deaths of all causes and the respective weekly pneumonia and influenza deaths in the 21 largest cities and their total. The latter is published regularly in Japanese during the influenza season as https://www.niid.go.jp/niid/ja/flu-m/2112-idsc/jinsoku/131-flu-jinsoku.html. Unfortunately, that publication ceased in March 2020 because it is intended for influenza. The outbreak peak in Japan was April 3[11]: excess mortality cannot be detected later than April. Instead, we applied the former to the all causes of death in April in Japan. Excess mortality is defined as the difference between the actual number of deaths and an epidemiological threshold. The epidemiological threshold is defined as the upper bound of the 95% confidence interval (CI) of the baseline. The baseline is defined as the number of deaths that are likely to have occurred if an influenza outbreak had not occurred. Therefore, if the actual deaths are fewer than the epidemiological threshold, then excess mortality is not inferred. The data used for this study were monthly deaths of all causes from 1987 through April 2020 [12] . Our NIID model, the Stochastic Frontier Estimation [13] [14] [15] [16] [17] [18] [19] , is presented as where D t represents all causes of death in month/year t, T t denotes the linear time trend, and M it is the dummy variable for a month, which is one if t is the i-th month and otherwise zero. Moreover, ν t and ω t are stochastic variables as ν t ~N(0, μ 2 ) and ω t ~N(0,ξ 2 ); they are mutually independent. Although ν t represents stochastic disturbances, ω t denotes non-negative deaths attributable to influenza. These disturbance terms in this model are parameterized by two parameters: ξ /μ and (μ 2 +ξ 2 ) 0.5 . If the null hypothesis ξ /μ=0 is not rejected, then the Stochastic Frontier Estimation model is inappropriate. We used only published data. No area of ethical concern is applicable to this study or the data used for it. Figure 1 presents observed deaths, the estimated baseline, and its threshold. Figure 2 specifically depicts the last year. Because the totals in March and April were lower than the baseline and therefore the threshold, no significant excess mortality was found in March-April, 2020, when the COVID-19 outbreak occurred in Japan. This In Tokyo, 1, 16, and 122 deaths were attributed to COVID-19 during February-April. Tokyo accounted for more than one fourth of the COVID-19-related deaths nationwide. However, the population in Tokyo is only one-tenth of the national population. Therefore, the proportion of deaths attributable to COVID-19 might be higher than 1%. In Tokyo, one might find some significant excess mortality because of COVID-19. Unfortunately, total deaths by prefecture for April, 2020 have not been reported yet. Using pneumonia death data instead of total death data might be better to evaluate excess mortality caused by COVID-19. However, application rule of tthe International Classification of Diseases was revised on January 2017, after which pneumonia deaths decreased by approximately 25%. April 2020 was the fourth April since that of 2017. Therefore, April 2020 data must be compared to data of only three earlier years. Therefore, it might be inappropriate to measure excess mortality attributable to COVID-19 using pneumonia deaths only. No significant excess mortality was found in March or April, 2020 when the COVID-19 outbreak occurred in Japan. Nevertheless, it might be important to continue to monitor excess mortality of COVID-19 carefully after May 2020. We acknowledge Dr. Nobuhiko Okabe, Kawasaki City Institute for Public Health, Dr.Kiyosu Taniguchi, National Hospital Organization Mie National Hospital, and Dr.Nahoko Shindo, WHO for their helpful support. The authors have no conflict of interest to declare. Assad Formulation and estimation of stochastic frontier production function models On the estimation of technical inefficiency in the stochastic frontier production function model Cost inefficiency in Washington Hospitals: A stochastic frontier approach using panel data Frontier Estimation: How useful a tool for health economics Managed care and technical efficiency